Abstract: 1,5-anhydroglucitol (1,5-AG) is sensitive and rapid to glycemic fluctuations. It is important for short-term glycemic monitoring, as it can reflect the glycemic fluctuations within the last 1– 2 weeks, as well as postprandial hyperglycemia. Numerous studies have demonstrated that 1,5-AG is associated with diabetic nephropathy, diabetic retinopathy, diabetic cardiovascular diseases, diabetic cerebrovascular diseases, diabetic neurodegeneration, and diabetic pregnancy complications. Therefore, 1,5-AG has potential application value in the risk stratification of diabetes complications and can serve as a complementary biomarker for the risk assessment of diabetes complications. Salivary 1,5-AG, as a non-invasive indicator for glycemic monitoring, is well accepted by patients with remarkable advantages in compliance and shows promising clinical application prospects. However, the relevant detection methods still need to be optimized and improved. This review summarizes the basic characteristics of 1,5-AG and systematically elaborates its clinical application value and research status in diabetes complications, aiming to provide a reference for the rational clinical application and future research of 1,5-AG. Keywords: diabetes, glycemic control, complementary biomarker, assessment
Xu et al. (Fri,) studied this question.